Neuroscience的老年痴呆药物VG-3927在早期试验中显示了希望,计划在2025年进一步试验。 Vigil Neuroscience's Alzheimer's drug VG-3927 shows promise in early trials, with plans for further testing in 2025.

Neuroscience的老年痴呆的药物候选者VG-3927在第一阶段试验中显示出令人乐观的结果,显示了良好的安全和可容忍性,没有发生严重的不利事件。 Vigil Neuroscience's Alzheimer's drug candidate, VG-3927, has shown promising results in a Phase 1 trial, demonstrating good safety and tolerability with no serious adverse events. 该药物有效地接触其目标,并显示出TREM2的刺激性活动。 The drug effectively engages its target and shows TREM2 agonist activity. Vigil 计划在 2 年第三季度开始 2025 期试验，每日剂量为 25 毫克。 Vigil plans to begin a Phase 2 trial with a 25mg daily dose in the third quarter of 2025. 分析师认为,根据药物的初步成功情况,该公司的价值被低估。 Analysts view the company as undervalued based on the preliminary success of the drug.